Valoración de los niveles de PCR tras artroplastia total de cadera

Objetivo: Determinación de la respuesta fisiológica de la Proteína C Reactiva (PCR) y la velocidad de sedimentación glomerular (VSG) tras la artroplastia total de cadera (ATC) no infectada. Material y Métodos: se realizó un estudio descriptivo sobre 20 pacientes afectos de coxartrosis primaria e intervenidos mediante ATC (18 pacientes tipo Auto-fit cementada y 2 pacientes tipo Prophor no cementada). Se determinaron los valores de VSG, PCR, fibrinógeno, hematocrito, hematíes y temperatura corporal matinal preoperatoriamente y en los días 1º, 2º, 3º, 7º, decimocuarto y a los 3 meses tras la intervención. Resultados: Se realizó el test de ANOVA para medidas repetidas con los valores obtenidos. Existieron diferencias significativas entre los niveles de PCR medidos en los diferentes momentos del estudio (p<0,001), alcanzando los niveles máximos dicho parámetro el 2º día postoperatorio y descendiendo sensiblemente a partir del 7º día postintervención. Conclusiones: La permanencia de valores altos de PCR o la aparición de nuevos picos tras el 2º -3er día postoperatorio puede ser un indicador de complicaciones graves en la ATC.Objectives: To determine the physiological answer of the reactive protein C (RPC) and the speed of globular sedimentation (SGS) after non infected total hip arthroplasty (THA). Material and methods: a descriptive study on a total sample of 20 patients suffering primary coxarthrosis and operated with THA was performed (18 patients with cemented Auto-Fit Prosthesis and 2 patients with cementless Prophor Prosthesis). The values of SGS, RPC, fibrinogen and morning body temperature were determined before the surgical proce- dure and on day 1, 2, 3, 7, 14 and 90 after it. Results: an ANOVA test was used for repeated measurements of the obtained results. There were statistically significant differences in the levels of RPC obtained in the different days of the study (p<0.001), obtaining the highest levels of it on day 2 after surgery and highly decreasing from day 7 after surgery onwards. Conclusions: the maintenance of increased levels of RPC or the appearance of new peaks after the day 2 or 3 after surgery may be an indicator of severe complications in THA

COVID-19 outbreaks in a transmission control scenario: challenges posed by social and leisure activities, and for workers in vulnerable conditions, Spain, early summer 2020

Severe acute respiratory syndrome coronavirus 2 community-wide transmission declined in Spain by early May 2020, being replaced by outbreaks and sporadic cases. From mid-June to 2 August, excluding single household outbreaks, 673 outbreaks were notified nationally, 551 active (>6,200 cases) at the time. More than half of these outbreaks and cases coincided with: (i) social (family/friends’ gatherings or leisure venues) and (ii) occupational (mainly involving workers in vulnerable conditions) settings. Control measures were accordingly applied

Public health surveillance: a pressing need.

[ES] La vigilancia en salud pública es el marco óptimo para el control de las enfermedades y la toma de decisiones basadas en la evidencia. Su definición incluye todos los ámbitos en los que la autoridad sanitaria interviene (análisis de la situación de salud, definición de prioridades, evaluación de políticas e investigación sanitaria)1,2. Además, es el origen de la decisión basada en la evidencia en salud pública y tiene valor incluso cuando no existen intervenciones posibles, ya que sus hallazgos contribuyen a la planificación o inspiran nuevas líneas de investigación2. Conscientes de la necesidad de ir más allá de las enfermedades infecciosas, en 1970, los Centers for Disease Control and Prevention de los Estados Unidos se reorientaron para incorporar las enfermedades crónicas y los factores de riesgo en sus sistemas de vigilancia, al igual que otros países desarrollados2-4. La vigilancia en salud pública solo tiene sentido cuando va unida a la puesta en marcha de medidas para el control de las enfermedades y de los riesgos para la salud; su meta es «información para la acción». Para ello, requiere el reconocimiento de la autoridad sanitaria, capacidad ejecutiva y una presencia relevante en las Administraciones sanitarias integrantes del conjunto del Estado. En Espana, ˜ el concepto de vigilancia en salud pública se ha incorporado recientemente con la Ley 33/2011 General de Salud Pública (LGSP). Dentro de este contexto, tratamos de valorar nuestra trayectoria histórica, así como sus debilidades y fortalezas, para poner en marcha un proyecto de vigilancia en salud pública en Espana. [EN] Objectives To describe anti-tuberculosis drug consumption in Spain for the period, 1985–1995, compare the associated time trend and geographical pattern against case reports of tuberculosis (TB), and estimate the number of persons undergoing anti-tuberculosis therapy in 1995. Methods The official Drug Database was used to ascertain consumption of anti-tuberculosis drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) in Spain during the period, 1985–1995. The technical units of measurement used for comparison purposes were daily defined dose (DDD) and DDD rate per day per 100,000 population. Annual trends and geographical patterns of consumption were plotted. The respective numbers of persons treated in 1995 with each of the four drugs were first estimated and then compared against TB case reports. Results There was an overall decline in the consumption of isoniazid, rifampicin and ethambutol over the period, 1985–1995, though the former two registered rises in 1991 and 1992. Pyrazinamide consumption showed growth throughout the study period. The highest 1995 consumption rates were registered by Galicia, Cantabria, Asturias, the Basque Country, Ceuta and Melilla, and the lowest by the Canary Islands and Navarre. Comparisons run against TB case reports revealed a greater degree of underreporting in certain provinces. In 1995, approximately 18,858 persons (48 per 100,000 population) must be assumed to have undergone pyrazinamide therapy in Spain, indicating that the reported TB rate of 22 per 100,000 population could well represent underreporting in excess of 100%. Conclusions The trend in anti-tuberculosis drug consumption reflects shifts in treatment guidelines and is compatible with a rise in TB incidence in recent years. Major underreporting of TB marked by wide inter-regional and -provincial differences was in evidence. Pyrazinamide consumption is probably the best indicator for estimating minimum TB incidence.S